What changed for Brain Cancer
A plain English summary of what recently moved in the public data Voxsanity tracks for Brain Cancer. Updated from government registries. Not medical advice.
How to read these changes: every figure on this page is the difference between two snapshots of what Voxsanity had tracked on each date. Voxsanity only began taking daily snapshots in July 2026 and is still ingesting the public registries, so a rise here is mostly our own coverage expanding rather than new research appearing. Read it as our tracked coverage growing, not as a claim about real-world research changing this fast: it overstates how much actually changed.
Comparing the two most recent snapshots, 27 July 2026 and 28 July 2026.
- Trials recruiting worldwide 563 to 581 (+18)
- Trials on record 3,061 to 3,144 (+83)
Newly subsidised on the PBS
No medicines were newly subsidised on the PBS for Brain Cancer in July 2026. Voxsanity tracks 4 PBS-subsidised medicines for this condition; none of them was listed for the first time this month.
Source: Pharmaceutical Benefits Scheme (PBS), © Commonwealth of Australia. Data used and redistributed under permission; not modified from its original wording where displayed verbatim.
Past updates
Tracking began in July 2026. Month on month changes will appear here once a second month of data has been recorded. Until then, the comparison above shows the most recent movement.
Recent trend
Weekly, most recent weeks (fills out to a monthly trend as history grows).
Recent trial results
The 30 most recent of 111 trials tracked for Brain Cancer that have reported results to a public registry.
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
-
NCT02595905 · results posted 8 April 2026
According to the results reported on ClinicalTrials.gov, this trial enrolled 344 people with breast cancer — 170 in a group receiving cisplatin (a chemotherapy) plus a placebo, and 174 in a group receiving cisplatin plus veliparib (a drug being tested). The trial was measuring how long people went without their cancer getting worse (called "progression-free survival"), how long people lived overall ("overall survival"), how many people's tumours shrank or disappeared ("response rate"), and how many people experienced some level of benefit ("clinical benefit rate"). Participants were divided in...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03475186 · results posted 13 March 2026
According to the results reported on ClinicalTrials.gov, this trial (NCT03475186) enrolled 75 participants, all of whom received the drug ramipril. The trial was measuring changes in brain function — specifically memory, attention, processing speed, and verbal fluency — in people undergoing radiotherapy (radiation treatment), most likely for a brain tumour. These thinking and memory skills were tested at the start of the trial and again about 10 weeks later (one month after radiotherapy finished). By that 10-week point, 56 participants had completed the assessments. The results from the ramipr...
-
NCT03868943 · results posted 21 October 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT03868943) looked at a medication called solriamfetol in people with cancer-related fatigue and sleep problems. Only 2 participants were enrolled in the study, and only 1 of them completed it. Because so few people took part, the results are extremely limited in what they can tell us. The trial was measuring serious unwanted health events (called "grade 3 or higher adverse events," meaning moderate-to-severe reactions on a standard medical rating scale), as well as sleep quality, daytime sleepiness, fatigue, mood, and think...
-
NCT03137888 · results posted 3 August 2025
According to the results reported on ClinicalTrials.gov, this trial enrolled 30 people, and all 30 completed the study. The trial was testing a type of brain cancer treatment that used a specialised MRI scanning technique (called structural MRI, or sMRI) to help guide radiation therapy, which was given alongside a chemotherapy medicine called temozolomide (TMZ). The trial was primarily looking at two things: whether the sMRI scans could be successfully matched up with standard clinical images and loaded into the radiation treatment system in a practical way, and how many unwanted side effects...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT02514915 · results posted 26 June 2025
According to the results reported on ClinicalTrials.gov, 24 people took part in this trial, and all 24 completed it. The trial looked at a type of precisely targeted radiation treatment called stereotactic radiosurgery. It measured two main things over time: first, whether tumours stayed under control (meaning they did not grow significantly compared to their size at the start of treatment); and second, how many participants were still alive at set points in time after treatment began. The reported data shows that when it came to tumour control, around 82 in every 100 participants (a proporti...
-
NCT04406272 · results posted 10 June 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT04406272) enrolled 15 people across three groups. Group A (6 people) received VB-111 both before and after surgery; Group B (4 people) received a placebo before surgery and then VB-111 after surgery; and Group C (5 people) received a placebo before surgery and then standard care after surgery. The trial was measuring things like immune cell activity in tumour tissue, serious unwanted health events (called serious adverse events, or SAEs), how many participants showed no sign of disease progression six months after surgery,...
-
NCT02655601 · results posted 8 June 2025
According to the results reported on ClinicalTrials.gov, this trial studied a drug called BMX-001 in people newly diagnosed with high-grade brain tumours (a type of aggressive brain cancer). The trial had two parts: a Phase 1 part to find a suitable dose of BMX-001 when given alongside standard radiation therapy and a chemotherapy drug called temozolomide (TMZ), and a Phase 2 part to look at how long patients lived. In the Phase 1 part, 17 people were enrolled across four different dose levels. In the Phase 2 part, 80 people received BMX-001 plus radiation and TMZ, and another 80 people receiv...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT01288235 · results posted 3 June 2025
According to the results reported on ClinicalTrials.gov, this trial enrolled 100 children who received proton radiotherapy (a type of radiation treatment that uses proton particles rather than standard X-rays). All 100 participants completed the study. The trial was measuring several things over time: whether participants developed hormonal (endocrine) problems, how their thinking and learning abilities changed, whether their cancer came back or spread, and whether they experienced significant side effects — including hearing loss. The reported data shows that, looking at hormonal problems, a...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT02521051 · results posted 13 May 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT02521051) looked at a combination of two medicines — alectinib and bevacizumab — in people with lung cancer that had spread to the brain. The trial had two stages: a Phase I stage to work out the right doses to use together, and a smaller Phase II stage to look further at those doses. In total, 11 people took part — 6 in the Phase I group and 5 in the Phase II group. No participants in either group were recorded as having left the study early. The reported data shows that, in the Phase I stage, the doses selected to carry...
-
NCT04006119 · results posted 18 April 2025
According to the results reported on ClinicalTrials.gov, this trial enrolled 40 people with recurrent or progressive glioblastoma (an aggressive form of brain tumour that had come back or kept growing). All participants received a combination of three treatments: an injection directly into the tumour (Ad-RTS-hIL-12), a daily oral tablet (veledimex), and an intravenous drug called cemiplimab. The trial was measuring two main things: how often and how seriously participants experienced unwanted side effects, and how long participants lived overall. The study was closed earlier than planned, whic...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT01604512 · results posted 8 April 2025
According to the results reported on ClinicalTrials.gov, this trial enrolled 148 people who had a brain tumour, and 141 of them completed the study. The trial was looking at two types of brain scans — a PET/CT scan and an MRI perfusion scan (a special MRI that measures blood flow in the brain) — to see whether these scans could help tell apart two things that can look similar on standard imaging after radiation treatment: damage caused by the radiation itself, versus the tumour growing back. The reported data shows that, of the 148 participants who started the study, 53 received the PET/CT sc...
-
NCT03642067 · results posted 28 January 2025
According to the results reported on ClinicalTrials.gov, a total of 59 people with colorectal cancer took part in this trial. They were divided into three groups based on certain biological markers (proteins) found in their tumour tissue: 12 people in Cohort A (who had both markers present), 15 in Cohort B (who had neither marker present), and 32 in Cohort C (who did not require marker testing). The trial was primarily measuring how many participants had their tumours noticeably shrink or disappear in response to the study treatment, a measure known as the "objective response rate." The repor...
-
NCT03276676 · results posted 27 December 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT03276676) enrolled a total of 10 participants, split into two groups: 4 people in Arm A and 6 people in Arm B. The trial was looking at brain tumour imaging, specifically whether two special PET scan tracers — [18F]FLT and [18F]Fluciclovine — could detect changes in tumour activity in the brain at different points during and after chemoradiotherapy (a combined chemotherapy and radiation treatment). The scans were taken before treatment, shortly after treatment finished, and again if the tumour appeared to change on an MRI...
-
NCT03296696 · results posted 29 October 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT03296696) tested a drug called AMG 596 in people with a type of brain tumour. A total of 30 people were enrolled across ten groups, each receiving a different dose of the drug — ranging from a very small 4.5 micrograms up to 6,000 micrograms — to help researchers understand how the body responded at each dose level. Almost all participants did not complete the full study period; only one person (in the 1,500 mcg group) was recorded as having completed the trial. The reported data shows that none of the participants in any...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04013672 · results posted 28 August 2024
According to the results reported on ClinicalTrials.gov, this trial enrolled 41 participants, all of whom were placed in Arm A — people with recurrent glioblastoma (a type of aggressive brain tumour) who had not previously received immunotherapy. Arm B, which was intended for people who had already tried a type of immunotherapy called anti-PD1 therapy, recorded zero participants enrolled. The trial was measuring how a combination of two treatments — Pembrolizumab (an immunotherapy drug) and SurVaxM (a vaccine-type treatment) — performed in this setting. Of the 41 people who started, 32 complet...
-
NCT01244737 · results posted 11 July 2024
According to the results reported on ClinicalTrials.gov, this trial enrolled 50 children in total across three groups: 16 with a new brain tumour diagnosis, 28 where doctors were concerned a brain tumour may have come back, and 6 whose brain tumour was being monitored during chemotherapy. The trial was measuring whether a specialised type of PET scan — using a radioactive tracer called FLT that is taken up by rapidly dividing cells — could reflect how actively the tumour cells were growing, as confirmed by laboratory analysis of tumour tissue removed during surgery. The reported data shows th...
-
NCT04796935 · results posted 6 June 2024
According to the results reported on ClinicalTrials.gov, this trial enrolled 42 people in the tactile imaging group (using a device called VerTouch) and 48 people in the control group (where the standard hand-feel method, called palpation, was used to locate the right spot on the back). The trial was looking at a procedure that involves inserting a needle into the spine — likely a spinal anaesthetic or similar — and was measuring how many times the needle needed to be moved or reinserted before the right location was reached. Both groups were made up of people undergoing this type of procedure...
-
NCT02014844 · results posted 29 May 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT02014844) looked at a drug called aldoxorubicin in people with a type of brain tumour. A total of 28 participants took part — 21 received a lower dose (250 mg/m²) and 7 received a higher dose (350 mg/m²). The trial's main goal was to measure the "objective response rate," which means the proportion of participants whose tumours showed a clear, measurable shrinkage or disappearance according to standard imaging criteria. The reported data shows that in the lower-dose group of 21 participants, zero participants met the crit...
-
NCT01494662 · results posted 22 May 2024
According to the results reported on ClinicalTrials.gov, this trial enrolled 140 people in total, divided into seven groups (called cohorts). Each cohort was made up of people with cancer that had spread to the brain (known as brain metastases), and the different groups reflected different cancer types or treatment situations. The trial was measuring how often tumours in the brain shrank or disappeared in response to treatment, as well as how long participants went without their disease getting worse, and how long they survived overall. The reported data shows that the main measurement — the...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03581292 · results posted 23 April 2024
According to the results reported on ClinicalTrials.gov, this trial enrolled 38 people in total, split across two groups (called strata) based on their condition. Stratum 1 had 24 participants and Stratum 2 had 14. The trial was measuring how long people went without their disease getting worse or experiencing other serious events (called "event-free survival"), as well as how many people's tumours shrank during treatment and how many people were still alive at two years. The reported data shows that for the primary measure — event-free survival, expressed as a probability where 1.0 would mea...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT01854554 · results posted 2 January 2024
According to the results reported on ClinicalTrials.gov, this trial compared two types of radiation treatment for brain tumours: standard intensity modulated radiotherapy (IMRT) and a newer form called intensity modulated proton radiotherapy (IMPT). A total of 90 people took part — 48 in the IMRT group and 42 in the IMPT group. The main thing the trial was measuring was how long it took for participants to show a meaningful decline in thinking and memory skills (called "cognitive failure"), based on a set of six standardised tests covering memory, attention, and verbal skills. The reported da...
-
NCT02323880 · results posted 2 January 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT02323880) tested a drug called selinexor in children and young people with certain brain tumours (high-grade gliomas) and other solid tumours. A total of 59 participants were enrolled across eight different dosing groups, which varied by how much of the drug was given and how often (daily or weekly). The trial was organised into different parts — Part A (finding the right dose), Part B (a broader treatment group), and Part PK (focused on how the body processes the drug). Notably, the reported data shows that zero participa...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT02078648 · results posted 6 December 2023
According to the results reported on ClinicalTrials.gov, this trial (NCT02078648) enrolled 74 adults in total — 46 people in a group receiving a treatment called SL-701 combined with GM-CSF and Imiquimod, and 28 people in a group receiving SL-701 combined with Poly-ICLC and Bevacizumab. The trial was measuring a number of things, including whether certain serious side effects (called "regimen-limiting toxicities") occurred, whether any unexpected deaths occurred that were linked to the study drug, how many participants were still alive at 12 months, and how tumours responded to treatment over...
-
NCT01128218 · results posted 30 November 2023
According to the results reported on ClinicalTrials.gov, this trial involved 33 people in total across two phases. In Phase 1, 19 people were divided into five groups, each receiving a different dose of a substance called 5-ALA (ranging from 10 mg per kilogram of body weight up to 50 mg/kg), taken by mouth before brain surgery for malignant glioma (a type of brain tumour). The goal was to find a dose that did not cause serious side effects, and then to test how well that dose helped surgeons visually identify tumour tissue during surgery using a special blue light that makes certain tissue glo...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT00588523 · results posted 27 October 2023
According to the results reported on ClinicalTrials.gov, this trial enrolled 60 people who had been newly diagnosed with a type of brain tumour called anaplastic oligodendroglioma. Of those 60, 57 completed the study and 3 did not. The trial was looking at how long participants went without their disease getting worse after receiving a high-dose chemotherapy treatment that required support from their own stored blood stem cells (a process used to help the body recover after intensive chemotherapy). The reported data shows that the main thing being measured was "progression-free survival" — th...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03190967 · results posted 11 October 2023
According to the results reported on ClinicalTrials.gov, this trial (NCT03190967) was conducted in two stages. The first stage (Phase I) involved 12 people in total — 3 at the lowest drug dose, 3 at a middle dose, and 6 at the highest dose — and was designed to find the highest dose of the chemotherapy drug temozolomide (TMZ) that could be given alongside another drug called ado-trastuzumab (T-DM1) without causing too many serious side effects. The second stage (Phase II) was intended to compare T-DM1 alone against T-DM1 combined with TMZ in people with breast cancer that had spread to the bra...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT00626990 · results posted 11 September 2023
According to the results reported on ClinicalTrials.gov, this trial enrolled 751 people across four groups, all of whom had been diagnosed with a type of brain tumour (low-grade glioma). The four groups received different combinations of radiotherapy (RT) and a chemotherapy drug called temozolomide (TMZ): radiotherapy alone, radiotherapy with temozolomide given at the same time, radiotherapy followed by temozolomide given afterwards, or radiotherapy with temozolomide given both at the same time and afterwards. The trial was primarily measuring how long participants lived after joining the stud...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04410367 · results posted 1 August 2023
According to the results reported on ClinicalTrials.gov, this trial involved 23 participants who received an injection of a radioactive imaging agent called 18F-fluciclovine and then had a PET scan (a type of body imaging). All 23 participants completed the study. The trial was measuring how well the PET scan could identify whether a brain lesion was a returning cancer (called a brain metastasis) compared to the result of a tissue biopsy, which was used as the reference standard. Three independent readers assessed each scan and rated the level of tracer uptake (how much of the imaging agent wa...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04631029 · results posted 27 June 2023
According to the results reported on ClinicalTrials.gov, this trial (NCT04631029) enrolled 3 participants, all of whom completed the study. There was only one dosing group, referred to as Dose Level 1. The trial was testing a combination of four medicines — entinostat, atezolizumab, carboplatin, and etoposide — and was primarily looking at safety signals early in development, including how many participants experienced serious side effects and whether the dose caused what are called "dose limiting toxicities" (side effects severe enough to prevent continuing or increasing the dose). The repor...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT02573324 · results posted 11 May 2023
According to the results reported on ClinicalTrials.gov, this trial enrolled 691 participants across two main groups: 341 people received a placebo combined with radiation therapy and a chemotherapy drug called temozolomide (TMZ), and 344 people received an experimental drug called depatuxizumab mafodotin combined with the same radiation and TMZ. A small separate group of 6 people took part in an open-label sub-study also receiving depatuxizumab mafodotin with radiation and TMZ. All participants had been diagnosed with a type of brain tumour called glioblastoma. The trial was primarily measuri...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
See all 111 reported results for Brain Cancer
These are the results as reported to the registry, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
What is coming
AI generated pipeline summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to NIH funding data, brain cancer currently attracts a very large amount of public research funding in the United States, and that investment has remained broadly steady over recent years. This level of sustained commitment suggests that brain cancer is an established and active area of scientific inquiry, with researchers continuing to explore new approaches to understanding and treatin...
See the full Brain Cancer page
Not medical advice. Voxsanity republishes public government health data in plain English. These figures describe research and registry activity, not the suitability of any treatment for any person. Trial status can change; always verify current status directly with the trial site and confirm Australian availability with your doctor.